Effects of Dynorphin1−13 on Opiate Binding and Dopamine and GABA Uptake in a Cat Model of Stroke

  • Y. Hosobuchi
  • H. Kuroda
  • T. Matsui
Conference paper


Opiates are best known for their analgesic properties, but they have many other effects on central nervous system (CNS) functions, including respiration, temperature control, and behavior. We have reported that certain opiates also may produce recovery from cerebral ischemia [1, 2, 4, 9]. Subsequent studies performed by others to confirm this finding in some [4, 9–11], although not all [6, 8], cases indicated that, in both experimental animals and in humans, opiate agonists exacerbate the symptoms of stroke, whereas opiate antagonists may prolong survival and, in some cases, ameliorate neurological deficits. Dynorphin1–13, an endogenous opioid peptide with both agonist and antagonist properties [12, 13], also has been shown to improve survival in animals [3].


Middle Cerebral Artery Opiate Receptor Scatchard Plot Endogenous Opioid Peptide Opiate Antagonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Baskin DS, Hosobuchi Y (1981) Naloxone reversal of ischemic neurological deficits in man. Lancet 2:272–275PubMedCrossRefGoogle Scholar
  2. 2.
    Baskin DS, Hosobuchi Y, Grevel JC (1986) Treatment of experimental stroke with opiate antagonists: Effects on neurological function, infarct size, and survival. J Neurosurg 64:99–103PubMedCrossRefGoogle Scholar
  3. 3.
    Baskin DS, Hosobuchi Y, Loh HH, Lee NM (1984) Dynorphin (1’13) improves survival in cats with focal cerebral ischemia. Nature 312:551–552PubMedCrossRefGoogle Scholar
  4. 4.
    Baskin DS, Kieck CF, Hosobuchi Y (1984) Naloxone reversal and morphine exacerbation of neurologic deficits secondary to focal cerebral ischemia in baboons. Brain Res 290:289–296PubMedCrossRefGoogle Scholar
  5. 5.
    Brandt NJ, Terenius L, Jacobsen BB, Klinken L, Nordius A, Brandt S, Blegvad K, Yssing M (1980) Hyperendorphin syndrome in a child with necrotizing encephalomyelopathy. N Engl J Med 303:914–916PubMedCrossRefGoogle Scholar
  6. 6.
    Cutler JR, Bredesen DE, Edwards R, Simon RP (1983) Failure of naloxone to reverse vascular neurological deficits. Neurology 33:1517–1518PubMedCrossRefGoogle Scholar
  7. 7.
    Garzon J, Sanchez-Blazquez P, Lee NM (1984) [3H]-ethylketocyclazocine binding to mouse brain membranes: Evidence for a kappa opioid receptor type. J Pharmacol Exp Ther 231:33–37PubMedGoogle Scholar
  8. 8.
    Holoday JN, D’Amato RJ (1982) Naloxone or the TRH fail to improve neurologic deficits in gerbil models of stroke. Life Sci 31:385–392CrossRefGoogle Scholar
  9. 9.
    Hosobuchi Y, Baskin DS, Woo SK (1982) Reversal of induced ischemic neurologic deficit in gerbils by the opiate antagonist naloxone. Science 215:69–71PubMedCrossRefGoogle Scholar
  10. 10.
    Iselin HA, Weiss P (1981) Naloxone reversal of ischemic neurologic deficit. Lancet 2:642–643CrossRefGoogle Scholar
  11. 11.
    Jovaily J, Davis JB (1982) Naloxone partially reverses neurologic deficits in some but not all stroke patients. Neurology 32:A194Google Scholar
  12. 12.
    Lee NM, Smith AP (1984) Possible regulatory function of dynorphin and its clinical implications. Trends Pharmacol Sci 5:108–110CrossRefGoogle Scholar
  13. 13.
    Talunay FC, Jen MF, Chang JK, Loh HH, Lee NM (1981) Possible regulatory role of dynorphin on morphine and α-endorphin-induced analgesia. J Pharmacol Exp Ther 219:296–298Google Scholar
  14. 14.
    Weinberger J, Cohen G (1982) The differential effect of ischemia on the active uptake of dopamine and aminobutyric acid, and glutamate by brain synaptosomes. J Neurochem 38:963–968PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 1988

Authors and Affiliations

  • Y. Hosobuchi
    • 1
  • H. Kuroda
    • 1
  • T. Matsui
    • 1
  1. 1.Department of Neurological Surgery, School of MedicineUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations